S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
MarketBeat Week in Review – 4/15 - 4/19
Morning sickness? Prenatal check-ups? What to know about new rights for pregnant workers
Tesla cuts US prices for 3 of its electric vehicle models after a difficult week
Moscow says 50 Ukrainian drones shot down as attacks spark fires at Russian power stations
A coffee roastery in Finland has launched an AI-generated blend. The results were surprising
Autoworkers union celebrates breakthrough win in Tennessee and takes aim at more plants in the South
The House votes for possible TikTok ban in the US, but don't expect the app to go away anytime soon
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
MarketBeat Week in Review – 4/15 - 4/19
Morning sickness? Prenatal check-ups? What to know about new rights for pregnant workers
Tesla cuts US prices for 3 of its electric vehicle models after a difficult week
Moscow says 50 Ukrainian drones shot down as attacks spark fires at Russian power stations
A coffee roastery in Finland has launched an AI-generated blend. The results were surprising
Autoworkers union celebrates breakthrough win in Tennessee and takes aim at more plants in the South
The House votes for possible TikTok ban in the US, but don't expect the app to go away anytime soon
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
MarketBeat Week in Review – 4/15 - 4/19
Morning sickness? Prenatal check-ups? What to know about new rights for pregnant workers
Tesla cuts US prices for 3 of its electric vehicle models after a difficult week
Moscow says 50 Ukrainian drones shot down as attacks spark fires at Russian power stations
A coffee roastery in Finland has launched an AI-generated blend. The results were surprising
Autoworkers union celebrates breakthrough win in Tennessee and takes aim at more plants in the South
The House votes for possible TikTok ban in the US, but don't expect the app to go away anytime soon
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
MarketBeat Week in Review – 4/15 - 4/19
Morning sickness? Prenatal check-ups? What to know about new rights for pregnant workers
Tesla cuts US prices for 3 of its electric vehicle models after a difficult week
Moscow says 50 Ukrainian drones shot down as attacks spark fires at Russian power stations
A coffee roastery in Finland has launched an AI-generated blend. The results were surprising
Autoworkers union celebrates breakthrough win in Tennessee and takes aim at more plants in the South
The House votes for possible TikTok ban in the US, but don't expect the app to go away anytime soon
NASDAQ:STAA

STAAR Surgical (STAA) Stock Price, News & Analysis

$46.39
-0.38 (-0.81%)
(As of 04/19/2024 ET)
Today's Range
$46.00
$47.33
50-Day Range
$29.49
$52.25
52-Week Range
$26.66
$73.13
Volume
396,855 shs
Average Volume
796,313 shs
Market Capitalization
$2.27 billion
P/E Ratio
107.88
Dividend Yield
N/A
Price Target
$46.38

STAAR Surgical MarketRank™ Stock Analysis

Analyst Rating
Hold
2.40 Rating Score
Upside/​Downside
0.0% Downside
$46.38 Price Target
Short Interest
Bearish
10.78% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.73
Upright™ Environmental Score
News Sentiment
0.44mentions of STAAR Surgical in the last 14 days
Based on 4 Articles This Week
Insider Trading
Acquiring Shares
$66,692 Bought Last Quarter
Proj. Earnings Growth
1,600.00%
From $0.03 to $0.51 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.24 out of 5 stars

Medical Sector

134th out of 909 stocks

Ophthalmic Goods Industry

1st out of 7 stocks

STAA stock logo

About STAAR Surgical Stock (NASDAQ:STAA)

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia. It markets its products to health care providers, including ophthalmic surgeons, vision and surgical centers, hospitals, government facilities, and distributors, as well as products are primarily used by ophthalmologists. The company sells its products directly through its sales representatives in the United States, Japan, Germany, Spain, Canada, the United Kingdom, and Singapore, as well as through own representatives and independent distributors in China, Korea, India, France, Benelux, Italy, and internationally. STAAR Surgical Company was incorporated in 1982 and is headquartered in Lake Forest, California.

STAA Stock Price History

STAA Stock News Headlines

Star Surgical Shines as U.S. Outlook Improves for 2024
STAAR Surgical Co. NASDAQ: STAA develops and manufactures intraocular lenses (IOL) used to replace a person's natural lenses during cataract surgery. Its portfolio includes the EVO line of Implantable Collamer Lenses (ICL) used for the treatment of nearsightedness (myopia), refractive error (astigmatism) and farsightedness (presbyopia).
Star Surgical Shines as U.S. Outlook Improves for 2024
STAAR Surgical is increasing its outlook and guidance as demand for its signature IOL procedure increases with an aging population
SHOCKING Crypto Leak…
A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024.
STAAR Surgical (NASDAQ:STAA) PT Raised to $53.00 at Mizuho
Staar Surgical Co STAA
SHOCKING Crypto Leak…
A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024.
STAA Apr 2024 30.000 call
STAA Apr 2024 35.000 put
Staar Surgical Co.
See More Headlines
Receive STAA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for STAAR Surgical and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/26/2024
Today
4/20/2024
Next Earnings (Estimated)
5/01/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Ophthalmic goods
Sub-Industry
Health Care Supplies
Current Symbol
NASDAQ:STAA
CUSIP
85231230
Employees
1,115
Year Founded
1982

Price Target and Rating

Average Stock Price Target
$46.38
High Stock Price Target
$57.00
Low Stock Price Target
$33.00
Potential Upside/Downside
0.0%
Consensus Rating
Hold
Rating Score (0-4)
2.40
Research Coverage
10 Analysts

Profitability

Net Income
$21.35 million
Pretax Margin
10.45%

Debt

Sales & Book Value

Annual Sales
$322.42 million
Cash Flow
$0.73 per share
Book Value
$7.91 per share

Miscellaneous

Free Float
48,328,000
Market Cap
$2.27 billion
Optionable
Optionable
Beta
0.86

Social Links

7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors Cover

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report

STAA Stock Analysis - Frequently Asked Questions

Should I buy or sell STAAR Surgical stock right now?

10 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for STAAR Surgical in the last twelve months. There are currently 6 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" STAA shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in STAA, but not buy additional shares or sell existing shares.
View STAA analyst ratings
or view top-rated stocks.

What is STAAR Surgical's stock price target for 2024?

10 analysts have issued 1-year price objectives for STAAR Surgical's shares. Their STAA share price targets range from $33.00 to $57.00. On average, they predict the company's share price to reach $46.38 in the next year. This suggests that the stock has a possible downside of 0.0%.
View analysts price targets for STAA
or view top-rated stocks among Wall Street analysts.

How have STAA shares performed in 2024?

STAAR Surgical's stock was trading at $31.21 at the beginning of the year. Since then, STAA stock has increased by 48.6% and is now trading at $46.39.
View the best growth stocks for 2024 here
.

When is STAAR Surgical's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 1st 2024.
View our STAA earnings forecast
.

How were STAAR Surgical's earnings last quarter?

STAAR Surgical (NASDAQ:STAA) released its quarterly earnings results on Monday, February, 26th. The medical instruments supplier reported $0.16 EPS for the quarter, missing analysts' consensus estimates of $0.17 by $0.01. The medical instruments supplier earned $76.27 million during the quarter, compared to analysts' expectations of $75.94 million. STAAR Surgical had a trailing twelve-month return on equity of 8.73% and a net margin of 6.62%. The firm's quarterly revenue was up 19.1% compared to the same quarter last year. During the same period in the prior year, the business earned $0.04 earnings per share.

What guidance has STAAR Surgical issued on next quarter's earnings?

STAAR Surgical issued an update on its FY 2024 earnings guidance on Wednesday, April, 17th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $340.0 million-$340.0 million, compared to the consensus revenue estimate of $337.2 million.

What is Caren Mason's approval rating as STAAR Surgical's CEO?

6 employees have rated STAAR Surgical Chief Executive Officer Caren Mason on Glassdoor.com. Caren Mason has an approval rating of 68% among the company's employees.

What other stocks do shareholders of STAAR Surgical own?

Based on aggregate information from My MarketBeat watchlists, some companies that other STAAR Surgical investors own include Tesla (TSLA), NVIDIA (NVDA), PayPal (PYPL), Walt Disney (DIS), CrowdStrike (CRWD), DocuSign (DOCU), Shopify (SHOP), Trade Desk (TTD), Teladoc Health (TDOC) and Roku (ROKU).

Who are STAAR Surgical's major shareholders?

STAAR Surgical's stock is owned by a number of retail and institutional investors. Top institutional investors include APEIRON CAPITAL Ltd (0.72%), State of Alaska Department of Revenue (0.06%), Maryland State Retirement & Pension System (0.04%) and GAMMA Investing LLC (0.00%). Insiders that own company stock include Aimee S Weisner, Broadwood Partners, LP, Caren L Mason, Elizabeth Yeu Lin, Graydon C Hansen, Hans-Martin Blickensdoerfer, James E Francese, Keith Holliday, Patrick F Williams and Samuel J Gesten.
View institutional ownership trends
.

How do I buy shares of STAAR Surgical?

Shares of STAA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Does STAAR Surgical have any subsidiaries?
The following companies are subsidiares of STAAR Surgical: Canon Staar, Frigitronics Inc., STAAR Japan Inc., STAAR Optical Equipment, STAAR Surgical AG, STAAR Surgical PTE. LTD, and Technology (Shanghai) Co. LTD.
Read More
This page (NASDAQ:STAA) was last updated on 4/21/2024 by MarketBeat.com Staff

From Our Partners